Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease
05 août 2022 08h30 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
AXIM Biotechnologies Celebrates Feature on the Vision is More Than 20/20™ Podcast
21 juil. 2022 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular...
Digital Vision Screening Platform Aims to Decrease Vision Loss Rates for Patients With Eye Disorders
24 mai 2022 11h00 HE
|
Retina Technologies, Inc
NEW YORK, May 24, 2022 (GLOBE NEWSWIRE) -- Retina Technologies, Inc. ("RetTech") is advancing the development of OcuVue™, an affordable, digital vision screening platform with integrated...
Tarsus to Present at Bank of America 2022 Healthcare Conference
06 mai 2022 09h00 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus Presents New Findings from Two Studies Demonstrating the Impact of Demodex Blepharitis at the ARVO 2022 Annual Meeting
05 mai 2022 08h30 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus Presents Results of Two Studies Highlighting Demodex Blepharitis Patient Impact and Burden at the ASCRS 2022 Annual Meeting
26 avr. 2022 08h30 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
NovaSight Announces Successful Results of Pivotal Amblyopia Treatment Trial
10 mars 2022 08h15 HE
|
NovaSight
AIRPORT CITY, Israel, March 10, 2022 (GLOBE NEWSWIRE) -- NovaSight, a pediatric-focused eyecare company, announced positive pivotal data from its multicenter, randomized, controlled trial of...
Tarsus Expands Executive Leadership Team with the Appointment of José Trevejo, M.D., Ph.D., as Chief Medical Officer
03 févr. 2022 09h00 HE
|
Tarsus Pharmaceuticals, Inc
Dr. Trevejo brings over 20 years of clinical development experience to Tarsus as it advances development of TP-03, the first potential treatment for Demodex blepharitis, and its pipeline programs ...
Tarsus Appoints Elizabeth Yeu, M.D., a Nationally Recognized Ophthalmologist and Eye Care Leader, to its Board of Directors
04 janv. 2022 09h00 HE
|
Tarsus Pharmaceuticals, Inc
Dr. Yeu brings over 20 years of eye care experience, and is a highly regarded leader in clinical care and new product innovation IRVINE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Tarsus...
Vision Benefits of America Donates $100,000 to the Pennsylvania Vision Foundation
16 déc. 2021 09h00 HE
|
VISION BENEFITS OF AMERICA
PITTSBURGH, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Vision Benefits of America, Inc. (VBA), a commercial group benefits organization, today announced a $100,000 donation to the Pennsylvania Vision...